Condition: Asthma
Intervention: Drug: Mepolizumab
Sponsor: GlaxoSmithKline
Not yet recruiting – verified February 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
GSK Files For Approval Of Mepolizumab In US, Europe For Eosinophilic Asthma – Nasdaq
|
GSK Files For Approval Of Mepolizumab In US, Europe For Eosinophilic Asthma
Nasdaq The submissions include a Biologics Licence Application to the US Food and Drug Administration as an add-on maintenance treatment for severe eosinophilic asthma in patients aged 12 years and older with a history of exacerbations. It also comprises a … |
View full post on asthma – Google News
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
Condition: Asthma
Interventions: Biological: Mepolizumab; Drug: Placebo; Drug: SOC
Sponsor: GlaxoSmithKline
Not yet recruiting – verified October 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Mepolizumab May Substantially Reduce Asthma Exacerbations – JAMA: The Journal of the American Medical Association
|
Mepolizumab May Substantially Reduce Asthma Exacerbations
JAMA: The Journal of the American Medical Association Mepolizumab, a humanized monoclonal antibody against interleukin-5, significantly reduced asthma exacerbations and improved quality of life among patients treated with inhaled glucocorticoids, according to a randomized, placebo-controlled trial with … |
View full post on asthma – Google News
Mepolizumab reduces exacerbations in severe eosinophilic asthma [MENSA trial] – 2 Minute Medicine
2 Minute Medicine |
Mepolizumab reduces exacerbations in severe eosinophilic asthma [MENSA trial]
2 Minute Medicine 1. The rate of asthma exacerbations was significantly reduced in patients with severe eosphinophilic asthma receiving either intravenous or subcutaneous mepolizumab, compared to patients receiving placebo. 2. The safety profile of mepolizumab was … Seven developments in asthma research |
View full post on asthma – Google News
Mepolizumab Relieves Severe Asthma, Trials Show – Medscape
Medscape |
Mepolizumab Relieves Severe Asthma, Trials Show
Medscape MUNICH, Germany — The monoclonal antibody mepolizumab delivered subcutaneously is a promising treatment for patients with severe eosinophilic asthma, according to the results of 2 new studies presented here at the European Respiratory Society … |
View full post on asthma – Google News
A respiratory expert undermines GSK’s case for new asthma drug mepolizumab – FierceBiotech
Reuters India |
A respiratory expert undermines GSK's case for new asthma drug mepolizumab
FierceBiotech Investigators for GlaxoSmithKline ($GSK) detailed their promising Phase III data for the IL-5 biologic mepolizumab in asthma today, noting that the injectable halved the rate of exacerbations among a group of patients with uncontrolled cases of the … UPDATE 1-Cost a focus as GSK takes lead in new wave of biotech lung drugs |
View full post on asthma – Google News
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
Condition: Asthma
Intervention: Biological: Mepolizumab
Sponsor: GlaxoSmithKline
Not yet recruiting – verified May 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Mepolizumab; Drug: Placebo
Sponsor: GlaxoSmithKline
Not yet recruiting – verified April 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
Condition: Asthma
Intervention: Biological: Mepolizumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Not yet recruiting – verified April 2013
View full post on ClinicalTrials.gov: asthma | received in the last 14 days